PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026Critical Care Medicine0 citations

398: Assessment of Corticosteroids in Community-Acquired Pneumonia

View Full Paper
NNNicholas T. NelsonNQNicholas J. QuinnNPNikhil Patel

Key Points

  • This study assessed the impact of corticosteroids on clinical outcomes for various severities of community-acquired pneumonia.
  • Retrospective cohort study of patients aged 18–65 with community-acquired pneumonia.
  • Exclusions included viral infections, hospital-acquired pneumonia, and chronic corticosteroid use.
  • Primary outcome measured composite clinical outcomes involving oxygen support and mortality.
  • Statistical analyses were conducted using chi-squared and Welch’s t-tests.
  • No significant difference in primary outcome (18.9% vs 17.2%) between corticosteroid and non-corticosteroid groups.
  • Higher ICU admission rates were noted in the corticosteroid group (30% vs 14%).
  • Numerically higher rates of acute kidney injury and bleeding in non-corticosteroid patients.
  • Findings suggest corticosteroids do not improve clinical outcomes for patients with pneumonia.

Abstract

Introduction: Community-acquired pneumonia(CAP) is a leading cause of morbidity and mortality worldwide. While recent guidelines endorse systemic corticosteroids(CS) in severe CAP, the role of CS across all severities remains unclear. Evidence outside ICU-level CAP is limited, raising questions about broader applicability. This study aimed to evaluate the impact of CS on oxygen support and other clinical outcomes in patients hospitalized with CAP of any severity. Methods: This was a retrospective cohort study of patients aged 18–65 years admitted for CAP to a Southeast Advocate Health hospital between December 2023 and April 2024. Patients with viral infections, hospital-acquired pneumonia, CAP diagnosis 7–14 days prior, chronic systemic CS use, pregnancy, or interfacility transfer were excluded. The primary outcome was a composite of increased oxygen support, vasopressor requirement, or in-hospital mortality. Secondary outcomes included individual composite components, acute kidney injury (AKI), major bleeding, insulin requirements, hospital length of stay, and ICU-, vasopressor-, and ventilator-free days. Chi-squared and Welch’s t-tests were used where appropriate. Results: Of 560 patients screened, 227 met inclusion criteria. Mean age was 51.5 years; 56% were white. Comorbidities included diabetes (38%), asthma (10%), and COPD (19%). Patients receiving CS (n=53) were older (54 vs 51 years, p=0.047), more frequently admitted to ICU (30% vs 14%, p=0.0118), and more likely to have COPD (40% vs 13%, p< 0.001). Despite these differences, the Charlson Comorbidity Index and pneumonia severity index were similar between groups. There was no significant difference in the primary composite outcome (18.9% with CS vs 17.2% without CS, p=0.95). Secondary outcomes were also not significantly different, though non-CS patients had numerically higher rates of AKI (16% vs 11%) and bleeding (24% vs 17%). Conclusions: Systemic CS were not associated with improved clinical outcomes, including oxygen support or mortality. While more patients in the CS group required ICU admission, outcomes did not differ significantly. Results should be interpreted cautiously due to lack of statistical power and baseline differences. Ongoing analysis with propensity score matching and a larger cohort is planned to validate findings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nelson et al. (2026) studied this question.

synapsesocial.com/papers/69c4cd25fdc3bde4489190c6https://doi.org/10.1097/01.ccm.0001183588.59286.25
Ask AI
Helpful
Bookmark
Share
View Full Paper